Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
60.6M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
12.1M
-
Shares change
-
-1.46M
-
Total reported value, excl. options
-
$65.6M
-
Value change
-
-$8.96M
-
Number of buys
-
11
-
Number of sells
-
-37
-
Price
-
$5.41
Significant Holders of Immuneering Corp - Class A Common Stock (IMRX) as of Q2 2022
50 filings reported holding IMRX - Immuneering Corp - Class A Common Stock as of Q2 2022.
Immuneering Corp - Class A Common Stock (IMRX) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.1M shares
of 60.6M outstanding shares and own 20.02% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4.14M shares), Cormorant Asset Management, LP (2.29M shares), CITADEL ADVISORS LLC (2.2M shares), BlackRock Inc. (1.36M shares), VANGUARD GROUP INC (741K shares), FMR LLC (223K shares), BUCKINGHAM STRATEGIC WEALTH, LLC (200K shares), SUVRETTA CAPITAL MANAGEMENT, LLC (200K shares), TD ASSET MANAGEMENT INC (148K shares), and MILLENNIUM MANAGEMENT LLC (129K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.